Morgan Stanley lowered the firm’s price target on NanoString (NSTG) to $8 from $14 and keeps an Equal Weight rating on the shares. Sentiment into Q3 earnings is “broadly cautious” on the Life Science Tools & Diagnostics group given tight customer budgets, destocking and China issues, the analyst tells investors in a group preview note. Stocks where 2024 estimates have “corrected sufficiently” and “bake in a metered recovery” could catch a bid into year-end, the analyst added, pointing to Thermo Fisher (TMO) and Natera (NTRA) as top picks among the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NSTG:
- 10x Genomics: UPC declines to issue second injunction against NanoString
- NanoString sees Q3 revenue ‘over’ $48M, consensus $46.26M
- NanoString and partners establish joint lab for spatial genomics in Singapore
- Largest borrow rate increases among liquid names
- Bold NanoString investors ‘hard to find’ after injunction, says Stifel